<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10901374</article-id><article-id pub-id-type="pmc">2363491</article-id><article-id pub-id-type="pii">6691230</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1230</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Braybrooke</surname><given-names>J P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Propper</surname><given-names>D J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>O&#x02019;Byrne</surname><given-names>K J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Koukourakis</surname><given-names>M I</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Patterson</surname><given-names>A V</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Houlbrook</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Love</surname><given-names>S D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Varcoe</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ganesan</surname><given-names>T S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Talbot</surname><given-names>D C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Harris</surname><given-names>A L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>ICRF Medical Oncology Unit, Churchill Hospital, Oxford, OX3 7LJ, UK</aff><aff id="aff2"><label>2</label>Department of Radiotherapy and Oncology, University Hospital of Iraklion, Iraklion, Crete, 71110, Greece</aff><pub-date pub-type="epub"><day>15</day><month>06</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>07</month><year>2000</year></pub-date><volume>83</volume><issue>2</issue><fpage>219</fpage><lpage>224</lpage><history><date date-type="received"><day>06</day><month>10</month><year>1999</year></date><date date-type="rev-recd"><day>02</day><month>03</month><year>2000</year></date><date date-type="accepted"><day>10</day><month>03</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Thymidine phosphorylase (TP) is an essential enzyme for the biochemical activation of 5-fluorouracil (5-FU). Interferon upregulates TP in vivo, although the dose and schedule of interferon for optimal biomodulation of 5-FU is not known. In this study, TP activity was measured in peripheral blood lymphocytes (PBLs) from patients with advanced carcinoma receiving treatment with 5-FU and folinic acid. Cohorts of patients were treated with interferon alpha (IFN&#x003b1;), immediately prior to 5-FU/folinic acid, at doses of 3 MIU m<sup>&#x02013;2</sup>, 9 MIU m<sup>&#x02013;2</sup>and 18 MIUm<sup>&#x02013;2</sup>. IFN&#x003b1; was administered on day 0 cycle two, day &#x02013;1 and day 0 cycle three and day &#x02013;2, day &#x02013;1 and day 0 cycle four. A fourth cohort was treated with IFN&#x003b1; 9 MIU m<sup>&#x02013;2</sup>three times per week from cycle 2 onwards. Twenty-one patients were entered into the study with 19 evaluable for response. Six patients (32&#x00025;) had stable disease and 13 (68&#x00025;) progressive disease. There were no grade-IV toxicities. TP activity was detected in PBLs from all patients with wide interpatient variability in constitutive TP activity prior to chemotherapy, and in response to IFN&#x003b1;. 5-FU/folinic acid alone did not induce TP activity but a single dose of IFN&#x003b1; led to upregulation of TP within 2 h of administration with a further increase by 24 h (signed rank test, <italic>P</italic> = 0.006). TP activity remained elevated for at least 13 days (signed rank test, <italic>P</italic> = 0.02). There were no significant differences in TP activity between schedules or with additional doses of IFN&#x003b1;. A single dose of IFN&#x003b1; as low as 3 MIU m<sup>&#x02013;2</sup>can cause sustained elevation of PBL TP activity in vivo indicating that biochemical markers are important pharmacodynamic endpoints for developing optimal schedules of IFN&#x003b1; for biomodulation of 5-FU. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>thymidine phosphorylase</kwd><kwd>interferon alpha</kwd><kwd>5-fluorouracil</kwd><kwd>folinic acid</kwd></kwd-group></article-meta></front></article>


